Online clinics and addiction-focused telehealth services have started to offer off-label prescriptions of GLP-1s to treat alcohol use disorder and other substance use disorders, the source reported. These offerings include both brand-name products and compounded formulations. The article noted that some companies are actively marketing these options directly to patients through telemedicine channels. Observers told the reporter that, in practice, this model can move much of the responsibility for assessing unapproved uses from clinicians and regulators onto patients themselves.
Pharmaceutical and biotech programs are moving in parallel. The source named several development efforts: Eli Lilly is investigating a drug called brenipatide; Altimmune is testing pemvidutide for alcohol use disorder; and Baseline Therapeutics is studying a GLP-1 receptor agonist across alcohol, cocaine, and methamphetamine use disorders. These programs indicate sustained interest in GLP-1 receptor agonists as potential pharmacologic options for addiction medicine. The source did not report trial results, dosing, or specific endpoints for these programs.
A photograph caption in the source reported that providers at a treatment center had prescribed GLP-1s to more than 650 patients with substance use disorders. That number suggests adoption at certain specialty centers and illustrates how prescribing can precede regulatory approval or definitive trial evidence. The article indicated that telehealth platforms are one route by which patients are accessing these prescriptions without waiting for formal FDA indications.
The source said addiction medicine specialists are hopeful the Food and Drug Administration may approve a new medication for alcohol use disorder in the near term — described in the article as the first such approval in two decades. The piece connected that potential regulatory action to the ongoing development programs noted above. The source did not provide a timeline for any FDA decision, nor did it list specific regulatory milestones or submitted applications.
Experts quoted or paraphrased in the source expressed concern about how telehealth prescribing for off-label uses shifts risk assessment. The article framed the issue as one where online platforms, by marketing unapproved applications, can place the burden of weighing uncertain benefits and harms on patients. The source did not provide primary safety data, adverse-event rates, or structured evidence supporting GLP-1 use for addiction; those data were not included in the provided extract. Clinicians and ethicists worry that marketing and direct-to-patient models can outpace evidence generation, complicating informed-consent conversations.
The publicly available portion of the article left several concrete gaps. The source extract did not contain randomized-trial outcomes, safety profiles, dosing regimens, duration-of-therapy recommendations, or comparative-effectiveness analyses for GLP-1s in substance use disorders. It also did not report whether telehealth platforms require baseline screening, laboratory monitoring, or integrated addiction counseling as part of their prescribing protocols. The remainder of the STAT News story was behind a STAT+ paywall; details beyond the excerpt were not accessible in the material provided to this rewrite.
Limitations and specific unanswered items documented in the source: the article did not report trial endpoints or safety data for brenipatide, pemvidutide, or the Baseline Therapeutics program; it provided no timeline for an FDA decision; and it contained no metrics about the scale of telehealth prescribing beyond the single treatment-center caption noting more than 650 patients. These concrete gaps represent short-term evidence limitations clinicians should consider when encountering off-label GLP-1 prescribing for addiction.
Next regulatory milestone implied by the reporting: investigators and industry are conducting development programs that could lead to an FDA filing for an alcohol use–disorder medication, but the source offered no date or formal submission plan. Clinicians and health systems weighing telehealth models will need trial data, formal labeling decisions, and clearer practice standards before off-label GLP-1 prescribing can be evaluated against standard-of-care treatments.
The article stopped at the STAT+ paywall, and that restriction prevented the source from reporting any further named expert testimony, operational details from telehealth companies, or additional numbers on prescribing volume. Those items remain unanswered in the provided text and should be sought in full reporting or primary trial publications before changing clinical practice.